CN102531878A - 丙戊酸钠的新晶型及其制备方法和用途 - Google Patents
丙戊酸钠的新晶型及其制备方法和用途 Download PDFInfo
- Publication number
- CN102531878A CN102531878A CN2012100285295A CN201210028529A CN102531878A CN 102531878 A CN102531878 A CN 102531878A CN 2012100285295 A CN2012100285295 A CN 2012100285295A CN 201210028529 A CN201210028529 A CN 201210028529A CN 102531878 A CN102531878 A CN 102531878A
- Authority
- CN
- China
- Prior art keywords
- sodium valproate
- crystal formation
- preparation
- organic solvent
- crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 title claims abstract description 76
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 title claims abstract description 74
- 229940084026 sodium valproate Drugs 0.000 title claims abstract description 73
- 239000013078 crystal Substances 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 39
- 239000003960 organic solvent Substances 0.000 claims description 14
- 238000002347 injection Methods 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 4
- 239000001961 anticonvulsive agent Substances 0.000 claims description 4
- 229960003965 antiepileptics Drugs 0.000 claims description 4
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 2
- 150000002576 ketones Chemical group 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 7
- 238000004090 dissolution Methods 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 4
- 230000007012 clinical effect Effects 0.000 abstract description 3
- 206010022086 Injection site pain Diseases 0.000 abstract 1
- 239000000047 product Substances 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 4
- 206010015037 epilepsy Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 206010034759 Petit mal epilepsy Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229960000604 valproic acid Drugs 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000033001 Complex partial seizures Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940028937 divalproex sodium Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 208000028316 focal seizure Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940023568 magnesium valproate Drugs 0.000 description 1
- LKLLHOIUJVEAGU-UHFFFAOYSA-L magnesium;2-propylpentanoate Chemical compound [Mg+2].CCCC(C([O-])=O)CCC.CCCC(C([O-])=O)CCC LKLLHOIUJVEAGU-UHFFFAOYSA-L 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- OMOMUFTZPTXCHP-UHFFFAOYSA-N valpromide Chemical compound CCCC(C(N)=O)CCC OMOMUFTZPTXCHP-UHFFFAOYSA-N 0.000 description 1
- 229960001930 valpromide Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000004552 water soluble powder Substances 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210028529.5A CN102531878B (zh) | 2011-02-25 | 2012-02-09 | 丙戊酸钠化合物及其制备方法和用途 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110045689.6 | 2011-02-25 | ||
CN201110045689 | 2011-02-25 | ||
CN201210028529.5A CN102531878B (zh) | 2011-02-25 | 2012-02-09 | 丙戊酸钠化合物及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102531878A true CN102531878A (zh) | 2012-07-04 |
CN102531878B CN102531878B (zh) | 2014-08-20 |
Family
ID=46340066
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210028838.2A Active CN102603510B (zh) | 2011-02-25 | 2012-02-09 | 丙戊酸钠的晶型及其制备方法和用途 |
CN201210028529.5A Active CN102531878B (zh) | 2011-02-25 | 2012-02-09 | 丙戊酸钠化合物及其制备方法和用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210028838.2A Active CN102603510B (zh) | 2011-02-25 | 2012-02-09 | 丙戊酸钠的晶型及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN102603510B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105017007A (zh) * | 2014-04-16 | 2015-11-04 | 四川科瑞德制药有限公司 | 一种丙戊酸钠化合物 |
CN111349003A (zh) * | 2018-12-20 | 2020-06-30 | 四川科瑞德制药股份有限公司 | 一种丙戊酸钠的制备方法 |
CN114685304A (zh) * | 2020-12-28 | 2022-07-01 | 湖南省湘中制药有限公司 | 丙戊酰胺球形结晶的制备及其在片剂上的应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114853595B (zh) * | 2022-06-01 | 2024-04-26 | 广州茂丰药业有限公司 | 一种丙戊酸钠、丙戊酸共晶的制备方法及其产品 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4988731A (en) * | 1979-08-20 | 1991-01-29 | Abbott Laboratories | Sodium hydrogen divalproate oligomer |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102079699B (zh) * | 2010-02-11 | 2013-09-04 | 四川科瑞德制药有限公司 | 丙戊酸钠的新晶型及其制备方法和用途 |
CN102241582B (zh) * | 2010-05-10 | 2013-02-27 | 山东方明药业集团股份有限公司 | 一种丙戊酸钠的合成工艺 |
-
2012
- 2012-02-09 CN CN201210028838.2A patent/CN102603510B/zh active Active
- 2012-02-09 CN CN201210028529.5A patent/CN102531878B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4988731A (en) * | 1979-08-20 | 1991-01-29 | Abbott Laboratories | Sodium hydrogen divalproate oligomer |
Non-Patent Citations (2)
Title |
---|
GJORGI PETRUSEVSKI,ET AL.,: "Solid-state forms of sodium valproate, active component of the anticonvulsant drug epilim", 《CHEM. MED. CHEM.》 * |
王学勤等: "丙戊酸钠合成新工艺", 《中国医药工业杂志》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105017007A (zh) * | 2014-04-16 | 2015-11-04 | 四川科瑞德制药有限公司 | 一种丙戊酸钠化合物 |
CN111349003A (zh) * | 2018-12-20 | 2020-06-30 | 四川科瑞德制药股份有限公司 | 一种丙戊酸钠的制备方法 |
CN111349003B (zh) * | 2018-12-20 | 2023-10-03 | 四川科瑞德制药股份有限公司 | 一种丙戊酸钠的制备方法 |
CN114685304A (zh) * | 2020-12-28 | 2022-07-01 | 湖南省湘中制药有限公司 | 丙戊酰胺球形结晶的制备及其在片剂上的应用 |
CN114685304B (zh) * | 2020-12-28 | 2024-01-09 | 湖南省湘中制药有限公司 | 丙戊酰胺球形结晶的制备及其在片剂上的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN102603510A (zh) | 2012-07-25 |
CN102531878B (zh) | 2014-08-20 |
CN102603510B (zh) | 2014-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103641822B (zh) | 一种卡格列净化合物及其药物组合物 | |
CN102531878B (zh) | 丙戊酸钠化合物及其制备方法和用途 | |
CN102516107A (zh) | 一类n-卞基苯胺衍生物及其用途 | |
CN101987094A (zh) | 门冬氨酸鸟氨酸注射液及其制备方法 | |
CN102320954B (zh) | 一种制备布洛芬大晶型的方法 | |
CN102079699B (zh) | 丙戊酸钠的新晶型及其制备方法和用途 | |
CN103360240A (zh) | 一种高纯度非诺贝酸的制备方法 | |
CN104628564A (zh) | 非诺贝特酸胆碱盐晶型及其制备方法 | |
CN103191051B (zh) | 一种奈拉滨注射液组合物及其制备方法 | |
CN101380329A (zh) | 一种精氨酸阿司匹林及其粉针剂的制备方法 | |
JP2017534635A (ja) | レバプラザン塩酸塩の結晶多形及びその調製方法 | |
CN105566314B (zh) | 一种盐酸替扎尼定化合物 | |
CN102746227B (zh) | 一种磷酸二甲啡烷晶型ⅱ及制备方法和药物组合物 | |
CN109820839A (zh) | 一种医用退热贴及其制备方法 | |
CN109528644A (zh) | 一种葡萄糖酸钙锌口服溶液及其制备方法 | |
CN109264746A (zh) | 一种药用级碳酸氢钠的制备方法 | |
CN104610153B (zh) | 奥扎格雷葡甲胺盐及其组合物、制备方法和用途 | |
CN105693813A (zh) | 一种甘草酸类小檗碱偶合物的制备及医药用途 | |
CN105254556A (zh) | 一种制备高纯度匹可硫酸钠的方法 | |
CN102503935A (zh) | 一种阿折地平新晶型及其制备方法和药用组合物 | |
CN100542517C (zh) | 牛黄解毒滴丸及其制备方法 | |
CN100358504C (zh) | 一种滋补肝肾的天麻醒脑滴丸及其制备方法 | |
CN104109128A (zh) | 卡博替尼苹果酸盐及其制备方法 | |
CN104356036A (zh) | 消旋卡多曲α 晶型及其制备方法 | |
CN110684066B (zh) | 胞二磷胆碱药物制剂及其脑梗塞急性期意识障碍的新用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 646100 Industrial Park, Fu Zhen Town, Luzhou, Sichuan, Luxian County Patentee after: Luzhou kered Pharmaceutical Co.,Ltd. Address before: 646106 Industrial Park, Fu Zhen Town, Luzhou, Sichuan, Luxian County Patentee before: SICHUAN CREDIT CHEMWERTH PHARMACEUTICAL Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 646100 Industrial Park, Fu Zhen Town, Luzhou, Sichuan, Luxian County Patentee after: Sichuan Tiandao Pharmaceutical Co.,Ltd. Country or region after: China Address before: 646100 Industrial Park, Fu Zhen Town, Luzhou, Sichuan, Luxian County Patentee before: Luzhou kered Pharmaceutical Co.,Ltd. Country or region before: China |